National readmission rates after surgical stabilization of traumatic rib fractures

Peter I. Cha, Nicholas A. Hakes, Jeff Choi, G. Rosenberg, L. Tennakoon, D. Spain, J. Forrester
{"title":"National readmission rates after surgical stabilization of traumatic rib fractures","authors":"Peter I. Cha, Nicholas A. Hakes, Jeff Choi, G. Rosenberg, L. Tennakoon, D. Spain, J. Forrester","doi":"10.4103/jctt.jctt_6_20","DOIUrl":null,"url":null,"abstract":"Introduction: Little is known about the risk of readmission after surgical stabilization of rib fractures (SSRFs). Materials and Methods: We performed a retrospective analysis of the National Readmissions Database, a representative sample of all hospitalized patients in the US, from January 2012 to December 2014. All inpatient encounters with a primary trauma diagnosis of rib fractures were included in the study. Patients who underwent SSRF were compared to those who did not. Outcomes evaluated included readmission frequency and mortality. Results: There were 411,169 patients admitted after trauma with rib fractures from 2012 to 2014; of these, 382 (<1%) underwent SSRF. Among non-SSRF patients, ≥3 rib fractures (odds ratio = 1.41, 95% confidence interval 1.23–1.62) were associated with readmission. Compared to the non-SSRF group, patients undergoing SSRF had a greater incidence of flail chest (26% vs. 2%; P < 0.0001), were more likely to have an injury severity score >15 (55% vs. 37%; P < 0.0001), and more likely to have a coexisting diagnosis of respiratory failure (35% vs. 18%, P < 0.0001). Despite the increased severity of injury among patients having SSRF, there was neither a statistically significant increase in patient deaths (<1% for SSRF vs. 4% no SSRF, P = 0.03) nor readmissions (<1% for SSRF vs. 1% for non SSRF, P = 1.0). Conclusions: Long-term readmission rates for traumatic rib fracture patients are low. If nonoperative management is pursued, the presence of ≥3 rib fractures increases the risk of readmission. Patients requiring SSRF do not have higher readmission or mortality rates despite having a higher burden of injury during their initial hospitalization, suggesting the clinical benefit of surgical fixation.","PeriodicalId":92962,"journal":{"name":"The journal of cardiothoracic trauma","volume":"5 1","pages":"16 - 21"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The journal of cardiothoracic trauma","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jctt.jctt_6_20","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

Introduction: Little is known about the risk of readmission after surgical stabilization of rib fractures (SSRFs). Materials and Methods: We performed a retrospective analysis of the National Readmissions Database, a representative sample of all hospitalized patients in the US, from January 2012 to December 2014. All inpatient encounters with a primary trauma diagnosis of rib fractures were included in the study. Patients who underwent SSRF were compared to those who did not. Outcomes evaluated included readmission frequency and mortality. Results: There were 411,169 patients admitted after trauma with rib fractures from 2012 to 2014; of these, 382 (<1%) underwent SSRF. Among non-SSRF patients, ≥3 rib fractures (odds ratio = 1.41, 95% confidence interval 1.23–1.62) were associated with readmission. Compared to the non-SSRF group, patients undergoing SSRF had a greater incidence of flail chest (26% vs. 2%; P < 0.0001), were more likely to have an injury severity score >15 (55% vs. 37%; P < 0.0001), and more likely to have a coexisting diagnosis of respiratory failure (35% vs. 18%, P < 0.0001). Despite the increased severity of injury among patients having SSRF, there was neither a statistically significant increase in patient deaths (<1% for SSRF vs. 4% no SSRF, P = 0.03) nor readmissions (<1% for SSRF vs. 1% for non SSRF, P = 1.0). Conclusions: Long-term readmission rates for traumatic rib fracture patients are low. If nonoperative management is pursued, the presence of ≥3 rib fractures increases the risk of readmission. Patients requiring SSRF do not have higher readmission or mortality rates despite having a higher burden of injury during their initial hospitalization, suggesting the clinical benefit of surgical fixation.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
全国创伤性肋骨骨折手术稳定后的再入院率
引言:对肋骨骨折手术稳定后再次入院的风险知之甚少。材料和方法:我们对国家自述数据库进行了回顾性分析,该数据库是2012年1月至2014年12月美国所有住院患者的代表性样本。所有被诊断为肋骨骨折的住院患者都被纳入了研究。将接受SSRF治疗的患者与未接受SSRF的患者进行比较。评估的结果包括再次入院频率和死亡率。结果:2012年至2014年,共有411169名肋骨骨折创伤后患者入院;其中382例(15例(55%对37%;P<0.0001),更有可能同时诊断为呼吸衰竭(35%对18%,P<0.0001)。尽管SSRF患者的损伤严重程度增加,患者死亡人数没有统计学意义的增加(SSRF<1%,无SSRF为4%,P=0.03),再次入院人数也没有统计学意义(SSRF>1%,非SSRF为1%,P=0.00)。结论:创伤性肋骨骨折患者的长期再入院率较低。如果采用非手术治疗,肋骨骨折≥3处会增加再次入院的风险。需要SSRF的患者尽管在最初住院期间有更高的损伤负担,但其再次入院率或死亡率并不高,这表明手术固定的临床益处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Minimal invasive approach for rib fractures: Feasibility and safety in a single-center experience Is flail chest correctly defined: A new definition is suggested Factors associated with early complications of surgical management due to penetrating laryngotracheal trauma in Colombia Posttraumatic pulmonary abscess Postoperative outcomes following surgical stabilization of rib fractures stratified by 5-factor modified frailty index
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1